Literature DB >> 21844312

In vitro activity of a novel broad-spectrum antifungal, E1210, tested against Aspergillus spp. determined by CLSI and EUCAST broth microdilution methods.

Michael A Pfaller1, Frederick Duncanson, Shawn A Messer, Gary J Moet, Ronald N Jones, Mariana Castanheira.   

Abstract

E1210 is a first-in-class broad-spectrum antifungal that suppresses hyphal growth by inhibiting fungal glycophosphatidylinositol (GPI) biosynthesis. In the present study, we extend these findings by examining the activity of E1210 and comparator antifungal agents against Aspergillus spp. by using the methods of the Clinical and Laboratory Standards Institute (CLSI) and the European Committee for Antimicrobial Susceptibility Testing (EUCAST) to test wild-type (WT) as well as amphotericin B (AMB)-resistant (-R) and azole-R strains (as determined by CLSI methods). Seventy-eight clinical isolates of Aspergillus were tested including 20 isolates of Aspergillus flavus species complex (SC), 22 of A. fumigatus SC, 13 of A. niger SC, and 23 of A. terreus SC. The collection included 15 AMB-R (MIC, ≥ 2 μg/ml) isolates of A. terreus SC and 10 itraconazole-R (MIC, ≥ 4 μg/ml) isolates of A. fumigatus SC (7 isolates), A. niger SC (2 isolates), and A. terreus SC (1 isolate). Comparator antifungal agents included anidulafungin, caspofungin, amphotericin B, itraconazole, posaconzole, and voriconazole. Both CLSI and EUCAST methods were highly concordant for E1210 and all comparators. The essential agreement (EA; ± 2 log(2) dilution steps) was 100% for all comparisons with the exception of posaconazole versus A. terreus SC (EA = 91.3%). The minimum effective concentration (MEC)/MIC(90) values (μg/ml) for E1210, anidulafungin, caspofungin, itraconazole, posaconazole, and voriconazole, respectively, were as follows for each species: for A. flavus SC, 0.03, ≤ 0.008, 0.12, 1, 1, and 1; for A. fumigatus SC, 0.06, 0.015, 0.12, >8, 1, and 4; for A. niger SC, 0.015, 0.03, 0.12, 4, 1, and 2; and for A. terreus SC, 0.06, 0.015, 0.12, 1, 0.5, and 1. E1210 was very active against AMB-R strains of A. terreus SC (MEC range, 0.015 to 0.06 μg/ml) and itraconazole-R strains of A. fumigatus SC (MEC range, 0.03 to 0.12 μg/ml), A. niger SC (MEC, 0.008 μg/ml), and A. terreus SC (MEC, 0.015 μg/ml). In conclusion, E1210 was a very potent and broad-spectrum antifungal agent regardless of in vitro method applied, with excellent activity against AMB-R and itraconazole-R strains of Aspergillus spp.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21844312      PMCID: PMC3194992          DOI: 10.1128/AAC.00570-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  26 in total

Review 1.  Aspergillosis: spectrum of disease, diagnosis, and treatment.

Authors:  Penelope D Barnes; Kieren A Marr
Journal:  Infect Dis Clin North Am       Date:  2006-09       Impact factor: 5.982

Review 2.  New agents for the treatment of fungal infections: clinical efficacy and gaps in coverage.

Authors:  Elias K Spanakis; George Aperis; Eleftherios Mylonakis
Journal:  Clin Infect Dis       Date:  2006-09-08       Impact factor: 9.079

3.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

Review 4.  Characterisation of breakthrough invasive mycoses in echinocandin recipients: an evidence-based review.

Authors:  Hsin-Yun Sun; Nina Singh
Journal:  Int J Antimicrob Agents       Date:  2009-12-29       Impact factor: 5.283

5.  EUCAST Technical Note on the method for the determination of broth dilution minimum inhibitory concentrations of antifungal agents for conidia-forming moulds.

Authors: 
Journal:  Clin Microbiol Infect       Date:  2008-10       Impact factor: 8.067

6.  Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence.

Authors:  Maiken Cavling Arendrup; Eleftheria Mavridou; Klaus Leth Mortensen; Eveline Snelders; Niels Frimodt-Møller; Humara Khan; Willem J G Melchers; Paul E Verweij
Journal:  PLoS One       Date:  2010-04-09       Impact factor: 3.240

7.  In vitro susceptibility of clinical isolates of Aspergillus spp. to anidulafungin, caspofungin, and micafungin: a head-to-head comparison using the CLSI M38-A2 broth microdilution method.

Authors:  M A Pfaller; L Boyken; R J Hollis; J Kroeger; S A Messer; S Tendolkar; D J Diekema
Journal:  J Clin Microbiol       Date:  2009-08-26       Impact factor: 5.948

8.  Breakthrough invasive aspergillosis in allogeneic haematopoietic stem cell transplant recipients treated with caspofungin.

Authors:  Adrienne Madureira; Anne Bergeron; Claire Lacroix; Marie Robin; Vanderson Rocha; Régis Peffault de Latour; Christèle Ferry; Agnès Devergie; Jordane Lapalu; Eliane Gluckmana; Gérard Socié; Mahmoud Ghannoum; Patricia Ribaud
Journal:  Int J Antimicrob Agents       Date:  2007-12       Impact factor: 5.283

Review 9.  Azole-resistance in Aspergillus: proposed nomenclature and breakpoints.

Authors:  Paul E Verweij; Susan J Howard; Willem J G Melchers; David W Denning
Journal:  Drug Resist Updat       Date:  2009-10-29       Impact factor: 18.500

10.  Epidemiological cutoffs and cross-resistance to azole drugs in Aspergillus fumigatus.

Authors:  Juan Luis Rodriguez-Tudela; Laura Alcazar-Fuoli; Emilia Mellado; Ana Alastruey-Izquierdo; Araceli Monzon; Manuel Cuenca-Estrella
Journal:  Antimicrob Agents Chemother       Date:  2008-05-12       Impact factor: 5.191

View more
  27 in total

1.  In vitro activities of amphotericin B, terbinafine, and azole drugs against clinical and environmental isolates of Aspergillus terreus sensu stricto.

Authors:  Mariana S Fernández; Florencia D Rojas; María E Cattana; María de Los Ángeles Sosa; Cristina A Iovannitti; Cornelia Lass-Flörl; Gustavo E Giusiano
Journal:  Antimicrob Agents Chemother       Date:  2015-03-30       Impact factor: 5.191

2.  In Vitro Activity of APX001A (Manogepix) and Comparator Agents against 1,706 Fungal Isolates Collected during an International Surveillance Program in 2017.

Authors:  M A Pfaller; M D Huband; R K Flamm; P A Bien; M Castanheira
Journal:  Antimicrob Agents Chemother       Date:  2019-07-25       Impact factor: 5.191

3.  Manogepix (APX001A) Displays Potent In Vitro Activity against Human Pathogenic Yeast, but with an Unexpected Correlation to Fluconazole MICs.

Authors:  Maiken Cavling Arendrup; Karin Meinike Jørgensen
Journal:  Antimicrob Agents Chemother       Date:  2020-06-23       Impact factor: 5.191

4.  The investigational agent E1210 is effective in treatment of experimental invasive candidiasis caused by resistant Candida albicans.

Authors:  Nathan P Wiederhold; Laura K Najvar; Annette W Fothergill; Dora I McCarthy; Rosie Bocanegra; Marcos Olivo; William R Kirkpatrick; Michael P Everson; Frederick P Duncanson; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

5.  Activities of E1210 and comparator agents tested by CLSI and EUCAST broth microdilution methods against Fusarium and Scedosporium species identified using molecular methods.

Authors:  Mariana Castanheira; Frederick P Duncanson; Daniel J Diekema; Josep Guarro; Ronald N Jones; Michael A Pfaller
Journal:  Antimicrob Agents Chemother       Date:  2011-11-14       Impact factor: 5.191

6.  A complex game of hide and seek: the search for new antifungals.

Authors:  Huy X Ngo; Sylvie Garneau-Tsodikova; Keith D Green
Journal:  Medchemcomm       Date:  2016-05-17       Impact factor: 3.597

7.  In Vivo Pharmacokinetics and Pharmacodynamics of APX001 against Candida spp. in a Neutropenic Disseminated Candidiasis Mouse Model.

Authors:  Miao Zhao; Alexander J Lepak; Brian VanScoy; Justin C Bader; Karen Marchillo; Jamie Vanhecker; Paul G Ambrose; David R Andes
Journal:  Antimicrob Agents Chemother       Date:  2018-03-27       Impact factor: 5.191

Review 8.  Targeting the GPI biosynthetic pathway.

Authors:  Usha Yadav; Mohd Ashraf Khan
Journal:  Pathog Glob Health       Date:  2018-02-27       Impact factor: 2.894

9.  In Vitro Activity of Manogepix (APX001A) and Comparators against Contemporary Molds: MEC Comparison and Preliminary Experience with Colorimetric MIC Determination.

Authors:  Karin Meinike Jørgensen; Karen M T Astvad; Maiken Cavling Arendrup
Journal:  Antimicrob Agents Chemother       Date:  2020-07-22       Impact factor: 5.191

10.  Therapeutic Potential of Fosmanogepix (APX001) for Intra-abdominal Candidiasis: from Lesion Penetration to Efficacy in a Mouse Model.

Authors:  Annie Lee; Ning Wang; Claire L Carter; Matthew Zimmerman; Véronique Dartois; Karen Joy Shaw; David S Perlin; Yanan Zhao
Journal:  Antimicrob Agents Chemother       Date:  2021-03-18       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.